Genome News and Research

RSS

DNA Typewriter tracks cell divisions and developmental decisions in mice

Scientists have succeeded in reconstructing the family tree of cells in a developing mouse embryo. They recorded cells' relationships, starting when the fertilized egg first split in two and ending after the body with organs took shape.

8 Oct 2026

Combination therapy overcomes immunotherapy resistance in glioblastoma

Scientists at The Wistar Institute have identified a combination treatment that overcomes two of the biggest barriers to immunotherapy in glioblastoma.

8 Oct 2026

New SPARCS technology combines AI and microscopy to screen cells

New technology combines artificial intelligence and microscopy to screen cells at large scale.

8 Oct 2026

Study uncovers a protective role for microglia in Parkinson's disease

Researchers at the University of Oxford have uncovered a previously unrecognized protective role for microglia, the brain's resident immune cells, in Parkinson's disease.

7 Oct 2026

Ancient gut microbes migrated with humans across the globe

As waves of humans left Africa tens of thousands of years ago, eventually populating the entire planet, they were joined on their world-conquering ride by the trillions of microorganisms that compose the gut microbiome.

7 Oct 2026

Major global alliance invests billions to build predictive AI models of biology

Biohub, the U.S. Department of Energy, the National Institutes of Health, and new funding partners today announced a major expansion of an international effort to generate and make accessible the data enabling predictive AI models of biology.

7 Oct 2026

Skin biopsy offers less invasive diagnosis for mitochondrial disease

Researchers at Children's Hospital Colorado (Children's Colorado) and the University of Colorado Anschutz School of Medicine have published one of the largest studies to date evaluating advanced laboratory testing for mitochondrial disease, providing new evidence that a small skin biopsy can often help diagnose these rare and complex conditions without the need for more invasive procedures.

6 Oct 2026

Phase III trial tests MRD-guided treatment for patients with ER-positive/HER2-negative breast cancer

Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc., a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer.

5 Oct 2026

New workflow rapidly identifies deadly fungal bloodstream infections

Bloodstream infections are a persistent threat to hospitalized patients, and those caused by fungi are particularly dangerous. Candida species are responsible for most invasive fungal infections worldwide and rank among the leading causes of hospital-acquired bloodstream infections overall.

5 Oct 2026

Cambridge and London Life Sciences Showcase returns during JPM Healthcare Week 2027

o2h co-discovery has announced that the Cambridge × London Life Sciences Showcase will return for its second edition during J.P. Morgan Healthcare Week 2027 in San Francisco.

From o2h Group 5 Oct 2026

Dana-Farber research reveals possible new target for treatment of sickle cell and beta thalassemia

That pathway involves BACH2 and NRF2 and was discovered using a large genome-wide association study that enabled an analysis of genes related to fetal hemoglobin from a wide range of ancestries, including European, African, and Asian ancestries.

5 Oct 2026

Could the gut be priming the body for a more severe stroke?

Gut bacteria may prime immune cells to worsen stroke damage

2 Oct 2026

New project explores mitochondrial evolution across diverse life forms

A research consortium has generated the broadest look yet at the proteins that make up mitochondria, capturing the organelle's diversity across multiple branches on the tree of complex life.

1 Oct 2026

Varying mutation rates in healthy organs explain cancer risk

A new study by scientists at City of Hope® and TGen, part of City of Hope, found surprisingly large differences in the number of mutations present in organs of healthy individuals.

1 Oct 2026

Streamlining CRISPR workflows, from editing to analysis

INTEGRA's automated solutions optimize CRISPR workflows, enhancing gene editing efficiency and accelerating the path to innovative therapeutic developments.

From INTEGRA Biosciences 30 Sep 2026

What older adults do on screens may matter more than total screen time

Across 8,996 older adults in four cohorts, television viewing was associated with poorer global cognition, while computer use was associated with better cognitive performance, with the strongest positive associations at low-to-moderate levels of use. Mendelian randomization supported these opposing patterns and linked genetically predicted television viewing time to lower left insula volume, which accounted for an estimated 14.8% of its association with poorer cognitive performance.

29 Sep 2026

Bile DNA sequencing helps identify hidden pancreatobiliary tumors

Distinguishing malignant from benign biliary strictures remains a major clinical challenge. Endoscopic retrograde cholangiopancreatography (ERCP)-guided cytology and biopsy may be inconclusive, particularly in early-stage disease or when tissue is scarce.

29 Sep 2026

An approved Ebola antibody may miss its mark against Bundibugyo virus

Researchers analyzed 44 Bundibugyo virus genomes and modeled how approved and experimental Ebola antibodies might bind the virus’s glycoprotein. The models predicted disrupted binding for Ebanga, conserved targets for MBP134, and different binding behavior for the complete Inmazeb cocktail than for two of its antibodies alone; laboratory tests are needed to determine whether these findings translate into treatment benefit.

28 Sep 2026

Intentional substance exposures at school rise sharply among younger children

A new study found that rates of intentional substance exposures at school reported to U.S. poison centers increased substantially among elementary- and middle-school-aged children from 2000 through 2024, while high-school-aged adolescents continued to experience the highest rates of serious medical outcomes and hospital admissions.

28 Sep 2026